 5. Patients with triple negative breast cancer estrogen receptor-negative ER-, progesterone receptor-negative PR-, and human epidermal growth factor receptor 2-negative Her2- must also meet the following criteria: a. Must have received at least one prior chemotherapy regimen for locally advanced or metastatic disease; b. Must have received prior taxane therapy. 